secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-07-29T10:33:23+00:00
Accession:  0000885725-26-000051
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q2 net sales $5.44B (+7.5% reported); adjusted EPS $0.86 beats guidance
--------------------------------------------------------------------------------

- Net sales $5.442B, up 7.5% reported (guidance 5.5-7.5%); adjusted EPS $0.86 (guidance $0.82-$0.84).
- GAAP EPS $0.61 vs $0.53 YoY; net income $907M.
- Cardiovascular segment grew 8.3% reported; MedSurg 5.9%.
- Completed $2B accelerated share repurchase (~40M shares); invested $1.5B in MiRus for 34% stake and TAVR option.
- Clinical data: FRACTURE IVL trial met endpoints; FARAPULSE PFA showed superiority over drugs in AVANT GUARD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/0000885725-26-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/bsx-20260729.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer